ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

M Brines, AN Dunne, M van Velzen, PL Proto… - Mol Med, 2014 - araimpharma.com

... 6,7). To circumvent this problem, we have developed engineered proteins and peptides that
interact ... 8,9). One promising candidate is ARA 290, which is an 11-amino acid peptide mod- eled ...
The material for this study was pro- duced by Bachem (Weil am Rhein, Ger- many) and ...

Peptide synthesis, peptide modification and peptide library synthesis, please contact:

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com